Tags » Hemophilia A

Hemophilia A drug information!

The Danish pharmaceutical giant Novo Nordisk recently announced the application for a BLA and a marketing authorization application (MAA) for the long-acting hemophilia drug N8-GP to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), respectively. 89 more words

Latest News

Gene Therapy for Severe Hemophilia A

A family medicine physician cares for a family in which both the grandfather and young grandson have hemophilia A. Recently, the grandfather came for a check-up on his arthritis and asked the physician, “Is there anything new for hemophilia that can help my grandson avoid what I’ve been through over the years? 461 more words

NEWS

My Medicine

My Factor, Koate-DVI. I infuse this everyday for Immune Tolerance Therapy

Inhibitors

Roche's drug Hemlibra was approved by the FDA

Hemlibra was approved by the FDA as the first new drug to treat hemophilia A in the body in the past 20 years.

Sandra Horning, Roche’s chief medical officer and head of global product development, said: ” the approval of Hemlibra is of great significance for hemophilia A patients who have factor VIII inhibitors in the body.  54 more words

Latest News

Hemophilia A market key players, size, types, market growth and 2017-2022 forecasts

Hemophilia A Market

Summary:
Latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A – Pipeline Review, H2 2017, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape. 741 more words

Consumer Goods

FDA approves new treatment Hemlibra (emicizumab-kxwh) to prevent bleeding in certain patients with hemophilia A

FDA approves new treatment to prevent bleeding in certain patients with hemophilia A

The U.S. Food and Drug Administration today approved Hemlibra (emicizumab-kxwh) to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors. 644 more words

0rphan Drug Status

BioMarin to Begin Phase 3 Gene Therapy Trials for Hemophilia A

BioMarin announced the results from their ongoing Phase 1/2 gene therapy studies evaluating  BMN 270 for patients with hemophilia A. Based on encouraging data, Phase 3 studies are being planned to start later this year. 433 more words

NEWS